Skip to main content
Journal cover image

Prevalence and incidence of depressive symptoms and diagnosis of depression as associated with elevated amyloid among Medicare beneficiaries with cognitive impairment.

Publication ,  Journal Article
Bélanger, E; Jutkowitz, E; Shewmaker, P; Van Houtven, CH; Burke, JR; Plassman, BL; Shepherd-Banigan, M; Couch, E; Mills, C; Wetle, TT
Published in: J Affect Disord
August 1, 2023

BACKGROUND: Depression and cognitive impairment commonly co-occur, and it has been hypothesized that the two share pathological processes. Our objective for this study was to determine the relationship between elevated β-amyloid level and the prevalence and incidence of depressive symptoms and diagnosed depression over two years among fee-for-service Medicare beneficiaries with cognitive impairment. METHODS: We utilized data from the CARE-IDEAS cohort study (N = 2078) including two measures of depressive symptoms (PHQ-2) and administrative claims data to identify pre-scan and incident depression diagnosis in subsample of fee-for-service Medicare beneficiaries (N = 1443). We used descriptive statistics and Poisson regression models with robust covariance. RESULTS: Beneficiaries whose scan results indicated not-elevated β-amyloid were significantly more likely to have been diagnosed with depression pre-scan (46.4 % vs. 33.1 %). There was no significant association between elevated amyloid and the incidence of depressive symptoms or diagnosed depression. LIMITATIONS: The sample was limited to Medicare beneficiaries with cognitive impairment. Race/ethnic composition and education levels were not representative of the general population and there was substantial loss to follow-up. Mixed depressive / anxious episodes were captured as diagnoses of depression, potentially overestimating depression in this population. CONCLUSIONS: There was a high prevalence and incidence of diagnosed depression in this cohort of Medicare beneficiaries, but the incidence of depressive symptoms and diagnosed depression was not associated with elevated β-amyloid.

Duke Scholars

Published In

J Affect Disord

DOI

EISSN

1573-2517

Publication Date

August 1, 2023

Volume

334

Start / End Page

293 / 296

Location

Netherlands

Related Subject Headings

  • United States
  • Psychiatry
  • Prevalence
  • Medicare
  • Incidence
  • Humans
  • Depression
  • Cohort Studies
  • Cognitive Dysfunction
  • Amyloid
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bélanger, E., Jutkowitz, E., Shewmaker, P., Van Houtven, C. H., Burke, J. R., Plassman, B. L., … Wetle, T. T. (2023). Prevalence and incidence of depressive symptoms and diagnosis of depression as associated with elevated amyloid among Medicare beneficiaries with cognitive impairment. J Affect Disord, 334, 293–296. https://doi.org/10.1016/j.jad.2023.04.115
Bélanger, Emmanuelle, Eric Jutkowitz, Peter Shewmaker, Courtney H. Van Houtven, James R. Burke, Brenda L. Plassman, Megan Shepherd-Banigan, Elyse Couch, Caroline Mills, and Terrie T. Wetle. “Prevalence and incidence of depressive symptoms and diagnosis of depression as associated with elevated amyloid among Medicare beneficiaries with cognitive impairment.J Affect Disord 334 (August 1, 2023): 293–96. https://doi.org/10.1016/j.jad.2023.04.115.
Bélanger E, Jutkowitz E, Shewmaker P, Van Houtven CH, Burke JR, Plassman BL, et al. Prevalence and incidence of depressive symptoms and diagnosis of depression as associated with elevated amyloid among Medicare beneficiaries with cognitive impairment. J Affect Disord. 2023 Aug 1;334:293–6.
Bélanger, Emmanuelle, et al. “Prevalence and incidence of depressive symptoms and diagnosis of depression as associated with elevated amyloid among Medicare beneficiaries with cognitive impairment.J Affect Disord, vol. 334, Aug. 2023, pp. 293–96. Pubmed, doi:10.1016/j.jad.2023.04.115.
Bélanger E, Jutkowitz E, Shewmaker P, Van Houtven CH, Burke JR, Plassman BL, Shepherd-Banigan M, Couch E, Mills C, Wetle TT. Prevalence and incidence of depressive symptoms and diagnosis of depression as associated with elevated amyloid among Medicare beneficiaries with cognitive impairment. J Affect Disord. 2023 Aug 1;334:293–296.
Journal cover image

Published In

J Affect Disord

DOI

EISSN

1573-2517

Publication Date

August 1, 2023

Volume

334

Start / End Page

293 / 296

Location

Netherlands

Related Subject Headings

  • United States
  • Psychiatry
  • Prevalence
  • Medicare
  • Incidence
  • Humans
  • Depression
  • Cohort Studies
  • Cognitive Dysfunction
  • Amyloid